GlaxoSmithKline Pharma Share Price
GlaxoSmithKline Pharma Share Price Today
As of 5 Jul 2026, GlaxoSmithKline Pharma share price is ₹2,395.50. The stock opened at ₹2,415.80, compared to its previous close of ₹2,415.80. During today's trading session, GlaxoSmithKline Pharma share price moved in the range of ₹2,380.00 to ₹2,426.70, with an average price of ₹2,403.35 for the day. Looking at its last 52-week, the stock has touched a low of ₹2,088.10 and a high of ₹3,358.90. On the performance front, GlaxoSmithKline Pharma share price has declined by 3.56% over the last six months and is down 27.45% on a year-on-year basis.
GlaxoSmithKline Pharma Returns Calculator
GlaxoSmithKline Pharma Shareholder Returns
GlaxoSmithKline Pharma Share Price History
| Name | Mkt Cap Cr | P/E | P/B | ROE | D/E | ROCE | Book Value | Div. Yield | Turnover | EPS(TTM) |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | 4,49,048.00 | 39.02 | 5.37 | 13.74% | 0.61 | 17.33% | 93.24 | 0.85% | 0.56 | 10.90 |
| Divis Laboratories | 1,77,179.00 | 69.00 | 10.57 | 15.32% | 0.00 | 19.56% | 629.49 | 0.45% | 0.58 | 98.19 |
| Torrent Pharmaceuticals | 1,57,804.00 | 66.03 | 17.03 | 26.76% | 1.05 | 18.30% | 16.90 | 0.90% | 0.49 | 64.75 |
| Cipla | 1,17,642.00 | 25.47 | 2.87 | 11.79% | 0.00 | 15.66% | 2.89 | 1.06% | 0.49 | 43.52 |
| Dr. Reddy's Laboratories | 1,12,368.00 | 27.03 | 2.97 | 11.07% | 0.18 | 12.54% | 375.78 | 0.59% | 0.63 | 38.68 |
| Zydus Lifesciences | 1,10,651.00 | 21.60 | 4.08 | 18.59% | 0.31 | 17.35% | 235.25 | 0.09% | 0.39 | 35.38 |
| Lupin | 1,09,676.00 | 20.48 | 4.89 | 23.76% | 0.04 | 24.88% | 659.05 | 0.75% | 0.61 | 129.18 |
| Mankind Pharma | 1,02,729.00 | 53.00 | 6.30 | 11.74% | 0.34 | 13.13% | 397.02 | 0.04% | 0.54 | 49.37 |
| Aurobindo Pharma | 90,608.00 | 25.87 | 2.39 | 9.25% | 0.19 | 11.76% | 391.14 | 0.26% | 0.48 | 41.58 |
| Laurus Labs | 82,398.90 | 60.26 | 10.10 | 18.21% | 0.45 | 16.70% | 10.19 | 0.20% | 0.97 | 13.72 |
GlaxoSmithKline Pharma Financials
Income Statement · Consolidated
| Particulars | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Revenue | ₹3,821.67 | ₹3,749.21 | ₹3,453.71 | ₹3,251.72 |
| Other Income | ₹145.36 | ₹145.93 | ₹122.59 | ₹100.66 |
| Total Revenue | ₹3,967.03 | ₹3,895.14 | ₹3,576.30 | ₹3,352.38 |
| Total Expenses | ₹2,581.65 | ₹2,639.95 | ₹2,616.50 | ₹2,515.02 |
| Profit Before Tax | ₹1,406.01 | ₹1,259.88 | ₹816.19 | ₹836.40 |
| Tax | ₹370.03 | ₹332.30 | ₹226.23 | ₹228.76 |
| Profit After Tax | ₹1,035.98 | ₹927.58 | ₹589.96 | ₹607.64 |
| EPS - Basic | ₹61.15 | ₹54.76 | ₹34.83 | ₹36.05 |
| EPS - Diluted | ₹61.15 | ₹54.76 | ₹34.83 | ₹36.05 |
Cash Flow · Consolidated
| Particulars | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Profit before tax | ₹1,385.39 | ₹1,255.19 | ₹959.80 | ₹841.49 |
| Income before WC changes | ₹1,320.14 | ₹1,186.78 | ₹914.67 | ₹801.49 |
| Change in Assets | ₹55.14 | ₹29.53 | -₹107.15 | ₹51.14 |
| Change in Liabilities | -₹153.31 | ₹155.30 | ₹168.17 | -₹96.89 |
| Change in WC | -₹98.17 | ₹184.83 | ₹61.02 | -₹45.75 |
| Cash flow from Operations | ₹903.30 | ₹1,289.90 | ₹582.02 | ₹484.23 |
| Cash flow from Investing | ₹396.98 | -₹45.80 | ₹8.71 | ₹807.85 |
| Cash flow from Financing | -₹737.08 | -₹769.42 | -₹561.50 | -₹1,543.32 |
| Total Cash Flow | ₹563.20 | ₹474.68 | ₹29.23 | -₹251.25 |
| Cash (Start of the year) | ₹538.85 | ₹64.17 | ₹34.94 | ₹286.19 |
| Cash (End of the year) | ₹1,102.05 | ₹538.85 | ₹64.17 | ₹34.94 |
Balance Sheet · Consolidated
| Particulars | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Non-Current Assets | ₹717.67 | ₹698.18 | ₹758.20 | ₹832.32 |
| Current Assets | ₹3,606.20 | ₹3,409.88 | ₹2,798.42 | ₹2,494.26 |
| Total Assets | ₹4,323.87 | ₹4,108.07 | ₹3,556.62 | ₹3,326.58 |
| Current Liabilities | ₹1,779.10 | ₹1,905.15 | ₹1,524.95 | ₹1,326.37 |
| Net Current Asset | ₹1,827.09 | ₹1,504.73 | ₹1,273.47 | ₹1,167.89 |
| Non-Current Liabilities | ₹277.35 | ₹251.60 | ₹254.03 | ₹258.94 |
| Equity Capital | ₹2,267.42 | ₹1,951.31 | ₹1,777.64 | ₹1,741.27 |
| Total Equity & Liabilities | ₹4,323.87 | ₹4,108.07 | ₹3,556.62 | ₹3,326.58 |
Income Statement · Standalone
| Particulars | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Revenue | ₹3,790.20 | ₹3,723.49 | ₹3,407.25 | ₹3,216.34 |
| Other Income | ₹142.56 | ₹142.56 | ₹123.48 | ₹101.51 |
| Total Revenue | ₹3,932.76 | ₹3,866.05 | ₹3,530.73 | ₹3,317.86 |
| Total Expenses | ₹2,559.17 | ₹2,622.31 | ₹2,578.08 | ₹2,484.50 |
| Profit Before Tax | ₹1,376.23 | ₹1,248.44 | ₹809.04 | ₹832.39 |
| Tax | ₹364.40 | ₹329.39 | ₹224.35 | ₹227.69 |
| Profit After Tax | ₹1,011.82 | ₹919.05 | ₹584.69 | ₹604.71 |
| EPS - Basic | ₹59.59 | ₹54.01 | ₹34.51 | ₹35.88 |
| EPS - Diluted | ₹59.73 | ₹54.24 | ₹34.51 | ₹35.88 |
Cash Flow · Standalone
| Particulars | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Profit before tax | ₹1,373.59 | ₹1,243.74 | ₹952.65 | ₹837.49 |
| Income before WC changes | ₹1,308.77 | ₹1,174.77 | ₹906.51 | ₹796.63 |
| Change in Assets | ₹62.42 | ₹22.37 | -₹100.82 | ₹42.28 |
| Change in Liabilities | -₹169.67 | ₹163.81 | ₹165.37 | -₹81.30 |
| Change in WC | -₹107.25 | ₹186.18 | ₹64.55 | -₹39.02 |
| Cash flow from Operations | ₹881.42 | ₹1,280.03 | ₹578.94 | ₹487.94 |
| Cash flow from Investing | ₹385.25 | -₹36.53 | ₹14.97 | ₹805.19 |
| Cash flow from Financing | -₹737.07 | -₹769.42 | -₹561.50 | -₹1,544.18 |
| Total Cash Flow | ₹529.60 | ₹474.07 | ₹32.41 | -₹251.05 |
| Cash (Start of the year) | ₹536.22 | ₹62.15 | ₹29.74 | ₹280.79 |
| Cash (End of the year) | ₹1,065.82 | ₹536.22 | ₹62.15 | ₹29.74 |
Balance Sheet · Standalone
| Particulars | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Non-Current Assets | ₹731.79 | ₹717.38 | ₹781.96 | ₹860.98 |
| Current Assets | ₹3,543.12 | ₹3,383.55 | ₹2,765.84 | ₹2,466.72 |
| Total Assets | ₹4,274.91 | ₹4,100.93 | ₹3,547.80 | ₹3,327.70 |
| Current Liabilities | ₹1,757.11 | ₹1,900.81 | ₹1,510.94 | ₹1,317.03 |
| Net Current Asset | ₹1,786.01 | ₹1,482.73 | ₹1,254.90 | ₹1,149.69 |
| Non-Current Liabilities | ₹276.63 | ₹250.89 | ₹252.76 | ₹257.67 |
| Equity Capital | ₹2,241.17 | ₹1,949.23 | ₹1,784.09 | ₹1,753.00 |
| Total Equity & Liabilities | ₹4,274.91 | ₹4,100.93 | ₹3,547.80 | ₹3,327.70 |
About GlaxoSmithKline Pharma
GlaxoSmithKline Pharmaceuticals Limited is an India-based global healthcare company. The Company is engaged in the business of manufacturing, distributing and trading in pharmaceuticals. The Company has three product areas: vaccines, specialty and general medicine. Its general medicines business has a portfolio of medicines in anti-infectives, pain, vitamins medicine, nutritional, hormones, dermatologicals, respiratory and vaccines for adults and children. The Company's general medicine brands include Augmentin, Calpol, Ceftum, Eltroxin, CCM, Neosporin, Betnovate, Tenovate, T-bact and Physiogel. The Company's vaccine brands include Shingrix Herpes Zoster Vaccine, Infanrix Hexa, Synflorix, Boostrix, Havrix, Menveo, Fluarix Tetra and Varilrix. Its specialty medicine brands include Nucala, Seretide, and Trelegy Ellipta. Trelegy Ellipta, single inhaler triple therapy (SITT) for chronic obstructive pulmonary disease (COPD) patients. The Subsidiary of the Company is Biddle Sawyer Limited.
GlaxoSmithKline Pharma Financial Highlights
- Revenue: GlaxoSmithKline Pharma reported revenue of ₹3,967.03 crore in FY26 vs ₹3,895.14 crore in FY25. It showed an increase of 1.85% on a yearly basis.
- Operating Profit: GlaxoSmithKline Pharma reported an operating profit of ₹1,406.01 crore in FY26 vs ₹1,259.88 crore in FY25. It showed an increase of 11.60% on a year-on-year basis.
- Net Profit: GlaxoSmithKline Pharma reported a net profit of ₹1,035.98 crore in FY26 vs ₹927.58 crore in FY25. It showed an increase of 11.69% on a yearly basis.
GlaxoSmithKline Pharma Quarterly Result Highlights
- GlaxoSmithKline Pharma reported revenue of ₹1,031.25 crore in Mar 2026, compared with ₹1,073.38 crore in Dec 2025, representing a decrease of 3.92% on a quarter-on-quarter (QoQ) basis.
- GlaxoSmithKline Pharma reported an operating profit of ₹373.10 crore in Mar 2026, compared with ₹399.93 crore in Dec 2025, representing a decrease of 6.71% on a quarter-on-quarter (QoQ) basis.
- GlaxoSmithKline Pharma reported a profit of ₹277.86 crore in Mar 2026, compared with ₹295.62 crore in Dec 2025, reflecting a decrease of 6.01% on a QoQ basis.
- The earnings per share (EPS) of GlaxoSmithKline Pharma stood at ₹61.15 during Mar 2026.
Similar Stocks
FAQs on GlaxoSmithKline Pharma Share Price
What is GlaxoSmithKline Pharma share price today?
GlaxoSmithKline Pharma share price is ₹2,395.50 as on 03 Jul, 2026, 15:44 IST.
How has the GlaxoSmithKline Pharma share price performed in the past?
In the last 1 year, GlaxoSmithKline Pharma delivered a return of -27.45%. The GlaxoSmithKline Pharma share price hit a high of ₹3,358.90 and low of ₹2,088.10.
How much is the Mutual Fund shareholding in GlaxoSmithKline Pharma shares?
The Mutual Fund Shareholding in GlaxoSmithKline Pharma was 4.73% at the end of Mar 2026.
What is the the 52-week high and low of GlaxoSmithKline Pharma shares ?
The 52-week high and low of GlaxoSmithKline Pharma share is ₹3,358.90 and ₹2,088.10 as of 03 Jul, 2026.
What is the market cap of GlaxoSmithKline Pharma?
The market capitalisation of GlaxoSmithKline Pharma is ₹40,927.60 Crores as on 03 Jul, 2026.
What are the stock symbols of GlaxoSmithKline Pharma?
The stock symbol of GlaxoSmithKline Pharma is GLAXO on the NSE, 500660 on the BSE, and the ISIN is INE159A01016.
What was yesterday's closing price of GlaxoSmithKline Pharma shares ?
GlaxoSmithKline Pharma shares closed yesterday at ₹2,415.80 on NSE & ₹2,415.95 on BSE
How to buy GlaxoSmithKline Pharma shares?
To buy GlaxoSmithKline Pharma shares, open a demat account with Upstox and complete the KYC process. Once your account is set up, search for the stock and place your order.
Can I buy GlaxoSmithKline Pharma shares on Holidays?
No, shares of GlaxoSmithKline Pharma or any other publicly traded company cannot be bought or sold on holidays when the stock exchanges are closed. You can only buy or sell GlaxoSmithKline Pharma shares on days when the stock exchanges are open for trading. It's important to check the NSE & BSE holidays calendar, before placing any trades to avoid any inconvenience.
What is the PE and PB ratio of GlaxoSmithKline Pharma?
The PE and PB ratio of GlaxoSmithKline Pharma is 37.34 and 17.06 respectively, as on 03 Jul, 2026, 15:44 IST.